Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation September 14, 2024 — 08:18
LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024 August 27, 2024 — 11:00
Inaugural ‘Korea Medical Innovation Research Forum’ regular seminar, a success April 19, 2024 — 21:00
amfori extends its Quality Management Initiative (QMI) in three more key sourcing countries in Asia January 4, 2024 — 14:22
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma December 21, 2023 — 21:45
NaaS Technology Inc. Announces Closing of US$30 Million Private Placement of Convertible Note July 7, 2023 — 20:00
Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough June 5, 2023 — 11:51
World Intellectual Property Day 2023: The 133rd Canton Fair Further Enhances Intellectual Property Rights Protection, Maintaining a Secure International Trading Environment April 26, 2023 — 22:21
New Oriental Announces Results for the Third Fiscal Quarter Ended February 28, 2023 April 19, 2023 — 17:18
Sinopec’s Styrene Butadiene Copolymer (SBC) Project with 170,000 Tons/Year Production Capacity Goes into Operation April 10, 2023 — 22:06
Noah Holdings Comments on Certain Recent Developments Involving Silicon Valley Bank March 12, 2023 — 18:20
China’s First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List January 19, 2023 — 11:45
ZEASN Appoints Dr. Jack Q. Gao, Former President of Microsoft (China), as Chairman of Global Strategy Committee January 1, 2023 — 23:00
Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program July 25, 2022 — 21:59
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 July 4, 2022 — 13:34
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax’s (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL June 8, 2022 — 08:00
ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC June 8, 2022 — 08:00
131st Canton Fair: high-quality development of trade promotes global economic recovery May 3, 2022 — 22:42
Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead March 21, 2022 — 23:11
Tech China Tech Digest: DJI Banned From Using Figma Software; AI Chip Unicorn Cambrian’s CTO Resigns March 15, 2022 — 19:24
